Fig. 2

Monitoring cell surface rescue of a mutant intracellularly mis-localized membrane protein. a Cartoon depicting HA-FAP fused to the N-terminus of wild-type (WT) D2R or DRY-AAY (DRY) D2R and EYFP on the C-terminus. b Confocal imaging for EYFP-tagged WT-D2R or DRY-D2R treated with vehicle (DMSO) or the D2R antagonist spiperone [10 μM]. c Infrared plate imaging for membrane impermeable SCi1 bound to FAP-tagged WT- or DRY-D2R treated with DMSO or spiperone (S, 10 μM) overnight. d Quantification of triplicate experiments represented in panel (c) and normalized relative to WT-D2R surface expression (* denotes significant difference by ANOVA and post hoc Tukey-analysis). e Small-scale dose-response screen of overnight treatment with small molecule antagonists using quantitative infrared plate imaging (V, DMSO Vehicle; S, Spiperone; R, Risperidone; Q, Quetiapine; O, Olanzapine; C, Clozapine. 10-10 (-10) M to 10-5 (-5) M). f Quantification of triplicate experiments of the representative image in (e) and normalized to spiperone (S). g Infrared image of 10 μM spiperone DRY-D2R surface expression rescue for Z’-factor analysis. h Quantification of panel (g) and calculation of a Z’-factor (* denotes significant difference by student’s unpaired t-test)